Preeti Dabas

Dr. Preeti Dabas

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2023 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
PDPreeti Dabas
Preeti Dabas
ADAdithi Danda
Adithi Danda

6 November 2025 in Science
Verified
Journal Article
Closed access
PDPreeti Dabas
Preeti Dabas
MCMeritxell B. Cutrona
Meritxell B. Cutrona
WRWojciech Rosikiewicz
Wojciech Rosikiewicz
RKRyan P. Kempen
Ryan P. Kempen
PRPatrick Rodrigues
Patrick Rodrigues
AAAseem Z. Ansari
Aseem Z. Ansari
Distinct phosphorylation marks are placed on the carboxyl-terminal domain (CTD) of RNA polymerase II (Pol II) during different stages of gene transcription. These phospho-CTD marks function as a molecular recognition code for the recruitment of stage-specific effector proteins. Querying ~80% of the human kinome, we identified 117 kinases that phosphorylate the CTD with a high degree of positional selectivity. The unifying characteristic linking these diverse kinases is that they selectively regulate Pol II at signal-responsive genes. An example of such “direct-at-gene” Pol II regulation is displayed by epidermal growth factor receptor (EGFR), a cell surface receptor tyrosine kinase. More broadly, our atlas of CTD kinases implicates Pol II as a direct regulatory end point for signal-transducing kinases that govern cellular physiology and contribute to the etiology of numerous diseases.



22 July 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
ABAditya Barve
Aditya Barve
PDPreeti Dabas
Preeti Dabas
ACAdam Cornwell
Adam Cornwell
PSPramika Sriram
Pramika Sriram
AKAlex Kopyov
Alex Kopyov
SMShannon McKinney-Freeman
Shannon McKinney-Freeman
Sickle cell disease (SCD) is a blood disorder affecting millions worldwide. Emerging evidence reveals that SCD pathophysiology increases the risk of myeloid malignancies and hematopoietic stem cell (HSC) dysfunction, likely because of chronic stress on bone marrow. To investigate this further, we interrogated bone marrow hematopoietic stem and progenitor cells (HSPCs) from mice and individuals with SCD and observed molecular signatures of chronic cellular stress including oxidative stress, DNA damage, and hallmarks of senescence. Consistent with these findings, SCD HSPCs displayed transcriptomic dysregulation of senescence-associated molecular programs and diminished mitogen response with prolonged cell cycle kinetics during time-lapse live cell imaging. SCD mice displayed a marked loss of immunophenotypic bone marrow HSPCs by flow cytometry and functional blood repopulating HSPCs in transplantation studies, whereas human SCD bone marrow HSPCs exhibited poor ex vivo hematopoietic colony-forming ability, and these phenotypes were reversed after senescence-targeting therapy with either ABT-263 (navitoclax) or the combination of dasatinib and quercetin. Thus, treatment with senescence-targeting therapy improves bone marrow HSPC function in vivo in mice and ex vivo in cells from individuals with SCD and could represent a possible strategy to improve HSPC health, promote manufacture of high-quality bespoke clinical products, and potentially enhance the safety of potentially curative gene therapies using autologous HSPCs from individuals with SCD.

30 March 2026 in Experimental Hematology
Verified
Journal Article
Closed access
ABAditya Barve
Aditya Barve
PDPreeti Dabas
Preeti Dabas
TCTerri Cain
Terri Cain
SMShannon McKinney-Freeman
Shannon McKinney-Freeman